0918

“Industry 4.0 – what does it mean and why should biopharma care? In this month’s cover feature we ask biopharma industry experts for their view. Meanwhile, Upfront looks at a new not-for-profit company headed up by Power List alumni Martin Van Trieste, and a paper-based assay for spotting fake antibiotics. But in In My View, Maarten Van Baelen considers the unintended consequences of fighting counterfeit medicine… Also in this issue we find out what pharma can learn from Toyota in lean manufacturing, and how sharks can influence a new generation of biotherapeutics. Finally, we Sit Down With Danny Bar-Zohar, Global Head of Neuroscience Development at Novartis, Switzerland.”

Email*

Choose a password

I have read and understand the Privacy Notice *

Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

I want to stay up to date with the "Small Molecule" field I want to stay up to date with the Cell and Gene field I want to stay up to date with the Bioprocessing field

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

I want to receive an alert when the next issue is available online

Articles featured in this issue

Manufacture Advanced Medicine

Science Versus Sensationalism

09/12/2018 | James Strachan

Don’t give the journalists an excuse to fuel the hype machine.

Business & Regulation Business Practice

For Patients, Not Profits

09/12/2018

A new not-for-profit company will manufacture important generics in the US

Manufacture Vaccines

Just One Shot

09/12/2018 | Stephanie Vine

A vaccine using mRNA demonstrates potential for broad influenza protection.

Business & Regulation Business Practice

Knowing Your Values

09/12/2018 | Stephanie Vine

Does a medicine’s price consistently track with its benefits and value? Not in the US, according to a study.

Business & Regulation Business Practice

Let’s Talk About Mental Health

09/12/2018 | Roisin McGuigan

A recent survey examined the relationships – or lack thereof – between pharma companies and mental health patient groups

Manufacture Quality & Compliance

Don’t Have Your Fake, or Eat It

09/12/2018 | Joanna Cummings

Finding counterfeit antibiotics – using a color-changing paper test

Manufacture Business Practice

Business-in-Brief

09/12/2018 | Stephanie Vine

After many years of clinical trial failures in Alzheimer’s disease, pharma sees some positive results – although caution is recommended.

Manufacture Small Molecules

A “Wellcome” Sight

09/12/2018 | Joanna Cummings

A fresh take on an existing photography competition aims to display the diversity of science.

Manufacture Bioprocessing - Upstream & Downstream

Trials of a Medicine Maker

09/12/2018

Gene and Eva consider the importance of good record keeping.

Manufacture Standards & Regulation

The Costs of the Counterfeit Battle

09/12/2018 | Maarten Van Baelen

Fighting counterfeit medicines is a noble goal, but the financial burden of safety features may affect access to medicines in unintended ways.

Manufacture Biosimilars

The CHO’s Over: An Inflexion Point

09/12/2018 | Mark Emalfarb

Global healthcare costs and demands are changing, and it’s time to look beyond mammalian cell lines.

Manufacture Clinical Trials

Right for Patients?

09/12/2018 | Ellen Sigal

“Right to Try” legislation may have compassion at its heart, but it does not do enough to ensure patient protection.

Business & Regulation Technology and Equipment

Towards Industry 4.0

09/12/2018 | James Strachan

The fourth industrial revolution – Industry 4.0 – represents a shift in manufacturing mentality. Is biopharma ready?

Business & Regulation Small Molecules

Kaizen Chiefs

09/12/2018 | Chris Owen

The automotive sector – Toyota, in particular – is a rich source of inspiration for improving productivity.

Discovery & Development Business Practice

Antibody About Turn

09/12/2018 | Sam Cobb

A promising candidate is on the verge of entering clinical development… What happens when you see an opportunity to make it even better?

Manufacture Small Molecules

The Medicinal Chemistry Puzzle: Lessons Learned with James Hitchin

09/12/2018 | James Hitchin

From big pharma, to cancer research to a fast growing CRO, James Hitchin has gained multiple perspectives on a subject that has become his passion – medicinal chemistry.